Insilico Medicine
英矽智能
elsewhere's corpus does not cover Insilico Medicine as a direct subject. The bundle only mentions the company in passing: Sanofi partnered with Insilico Medicine in 2022 to use its AI-driven platform for drug development acceleration , and Qiming Venture Partners is noted as an investor . No entity card, founding details, strategy description, or dedicated coverage of the company itself is present.
AI-generated — may contain errors, please verify.
Insilico MedicineCompany
英矽智能
渲染中…
Mentioned in 4 articles
Coverage
AI for Science Investment and Entrepreneurship: Where Are the Opportunities in the Next Decade?
"That failed data is valuable."
Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
$1 Billion! BioMap and Sanofi Partner to Develop AI Drug Discovery Models Based on Large Foundation Models | BlueRun Ventures Headlines
The First Commercial Partnership Based on Large Language Models in the Life Sciences Sector
Hongshan Healthcare Investing: 17 Years From the Sidelines to Center Stage
Going earlier and deeper has become a defining feature of Hongshan's healthcare investments.
